Article

Allergan to file drug application for eyelash growth stimulant

Irvine, CA-Allergan Inc. intends to file a new drug application with the FDA by the end of the third quarter of this year for bimatoprost, a synthetic prostaglandin analog, as a treatment to stimulate eyelash growth.

Irvine, CA-Allergan Inc. intends to file a new drug application with the FDA by the end of the third quarter of this year for bimatoprost, a synthetic prostaglandin analog, as a treatment to stimulate eyelash growth.

The company said it has completed its clinical trial program demonstrating the drug’s patented formulation results in significant eyelash growth when applied directly to the base of the eyelashes.

“We are pleased with the results of our program and believe this innovative product, if approved, could meet a significant and currently unmet demand in the medical aesthetic marketplace,” said Scott Whitcup, MD, Allergan’s vice president, research and development.

If approved by the FDA for eyelash growth, the company estimates global peak sales for the drug could exceed $500 million per year.  

“The development of this innovative product stems from our 60-year expertise and leadership in prescription eye-care products,” said David E.I. Pyott, Allergan’s chairman of the board and chief executive officer.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.